The nosology and treatment options for cognitive impairment in Parkinson disease (PD) remains perhaps the greatest unmet clinical need.1 The reported frequency of mild cognitive impairment (MCI) in newly diagnosed PD has ranged from 22% to 43%.2,3 A proportion of those with PD-MCI progress to PD dementia (PDD), the prevalence of which is variously estimated between 24% and 31%,
Objective: To determine if blood neurofilament light chain (NfL) protein can discriminate between Parkinson disease (PD) and atypical parkinsonian disorders (APD) with equally high diagnostic accuracy as CSF NfL, and can therefore improve the diagnostic workup of parkinsonian disorders.
Methods: The study included 3 independent prospective cohorts: the Lund (n = 278) and London (n = 117) cohorts,
Most everyone has met a Parkinson’s patient; maybe a grandfather or grandmother, mother, or father, uncle, aunt or neighbor. Whoever it may be, the symptoms of slowed, difficult movement, stooped posture, fatigue, and lack of facial expression can have a negative impact on a person’s sense of well-being and health. Understanding the steps that can be taken by a patient and family member to help this person are vital to achieving positive outcomes for the person.
Parkinson’s disease, a chronic neurodegenerative disease of the central nervous system, affects 4% of the population worldwide over 80 years of age and is a leading cause of disability in the older population. As a movement disorder, it impairs a person’s ability to walk, dress, prepare meals, drive, eat, play sports, and think. The disease can affect both men and women,
Parkinson’s Disease or PD is a neurodegenerative disorder; it may progress slowly but worsens over time. Symptoms in the advanced stages of this disease can include slowed movements, tremors, and memory loss. Many sufferers find themselves increasingly dependent on their caregivers as their condition declines. No cure for PD has been discovered, but medications are available to reduce the effects of its symptoms.